Bevacizumab in clinical practice

Area of Science:

• Oncology
• Pharmacology

Background:

• Targeted cancer therapies, including angiogenesis inhibitors, represent a significant advancement.
• Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), is approved for various solid tumors.

Purpose of the Study:

• To review the side effects of bevacizumab observed in clinical trials.
• To outline guidelines for managing bevacizumab-associated adverse events.

Main Methods:

• Review of clinical trial data for bevacizumab.
• Analysis of published guidelines for adverse event management.

Main Results:

• Bevacizumab is generally well-tolerated.
• Key adverse events requiring monitoring include vascular and renal toxicities such as hypertension, proteinuria, thromboembolic events, and hemorrhage.

Conclusions:

• Optimal management of bevacizumab toxicity is crucial for patient safety.
• Patient education and adherence to management guidelines can facilitate prolonged therapy and improve clinical outcomes.